285 related articles for article (PubMed ID: 26628601)
1. Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort.
Greenberg JD; Palmer JB; Li Y; Herrera V; Tsang Y; Liao M
J Rheumatol; 2016 Jan; 43(1):88-96. PubMed ID: 26628601
[TBL] [Abstract][Full Text] [Related]
2. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
3. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
4. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
5. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.
Huscher D; Merkesdal S; Thiele K; Zeidler H; Schneider M; Zink A;
Ann Rheum Dis; 2006 Sep; 65(9):1175-83. PubMed ID: 16540552
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
[TBL] [Abstract][Full Text] [Related]
7. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
8. Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.
Feldman SR; Zhao Y; Shi L; Tran MH; Lu J
Arthritis Care Res (Hoboken); 2015 May; 67(5):708-17. PubMed ID: 25303478
[TBL] [Abstract][Full Text] [Related]
9. Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA.
Merola JF; Herrera V; Palmer JB
Clin Rheumatol; 2018 Oct; 37(10):2751-2761. PubMed ID: 30051284
[TBL] [Abstract][Full Text] [Related]
10. Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.
Yi E; Dai D; Piao OW; Zheng JZ; Park Y
J Manag Care Spec Pharm; 2021 Jan; 27(1):27-36. PubMed ID: 33043820
[TBL] [Abstract][Full Text] [Related]
11. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
12. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
[TBL] [Abstract][Full Text] [Related]
13. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis.
Al Sawah S; Foster SA; Goldblum OM; Malatestinic WN; Zhu B; Shi N; Song X; Feldman SR
J Med Econ; 2017 Sep; 20(9):982-990. PubMed ID: 28635342
[TBL] [Abstract][Full Text] [Related]
14. Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases.
Sheahan A; Anjohrin S; Suruki R; Stark JL; Sloan VS
Clin Rheumatol; 2024 Jun; 43(6):1897-1907. PubMed ID: 38658403
[TBL] [Abstract][Full Text] [Related]
15. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
[TBL] [Abstract][Full Text] [Related]
18. Counting Costs under Severe Financial Constraints: A Cost-of-Illness Analysis of Spondyloarthropathies in a Tertiary Hospital in Greece.
Tsifetaki N; Migkos MP; Papagoras C; Voulgari PV; Athanasakis K; Drosos AA
J Rheumatol; 2015 Jun; 42(6):963-7. PubMed ID: 25834213
[TBL] [Abstract][Full Text] [Related]
19. Economic impact of biologic utilization patterns in patients with psoriatic arthritis.
Schwartzman S; Li Y; Zhou H; Palmer JB
Clin Rheumatol; 2017 Jul; 36(7):1579-1588. PubMed ID: 28474139
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characteristics of Patients With Psoriatic Spondylitis Versus Those With Ankylosing Spondylitis: Features at Baseline Before Biologic Therapy.
Kim HA; Lee E; Park SY; Lee SS; Shin K
J Korean Med Sci; 2022 Aug; 37(33):e253. PubMed ID: 35996930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
